Pharnext recently provided an update from its ongoing Phase 3 clinical trials evaluating PXT3003 for treating Charcot-Marie-Tooth disease type…
Articles by Margarida Azevedo, MSc
Grünenthal, the Lead Discovery Center (LDC) and the Max-Planck Society have signed a research collaboration agreement to develop new…
The French biopharmaceutical company Pharnext recently announced that its candidate for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A) was…
Like many of us, people living with Charcot-Marie-Tooth (CMT)Â disease make resolutions to become healthier and more fit. But while…
True Reply recently committed to donating up to $200,000 from its cryptocurrency sale to support the Hereditary…
The online community GeneFo will hold a free webinar this month to provide those living with Charcot-Marie-Tooth (CMT)…
The heartwarming story of students from three Massachusetts high schools banding together to help raise money to find a cure…
The connection between artist Andrew Wyeth’s most famous painting, Christina’s World, and Charcot-Marie-Tooth (CMT), a group of inherited…
Flex Pharma has initiated its Phase 2 COMMIT trial to evaluate the drug candidate FLX-787 in patients with…
Cure CMT4J, a nonprofit foundation started by a family whose daughter was diagnosed with…